Interest in adoptive cell therapy for treating cancer is exploding owing to early clinical
successes of autologous chimeric antigen receptor (CAR) T lymphocyte therapy. However …

Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …

Chimeric antigen receptor (CAR)-modified natural killer (NK) cells show antileukemic activity
against acute myeloid leukemia (AML) in vivo. However, NK cell-mediated tumor killing is …

Adoptive cell therapies (ACT) based on chimeric antigen receptor (CAR)-modified immune
cells have made great progress with six CAR-T cell products approved by the US FDA for …

The incidence and mortality of cancer are the major health issue worldwide. Apart from the
treatments developed to date, the unsatisfactory therapeutic effects of cancers have not …

Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …

Despite advances in treatment for multiple myeloma, the majority of patients ultimately
develop relapsed disease marked by immune evasion and resistance to standard therapy …

Ligation of the inhibitory receptor NKG2A by its ligand HLA-E negatively regulates the
activation of natural killer (NK) cells, as well as subsets of CD8+ T cells and innate T cell …

Natural killer (NK) cells are potent cytotoxic innate lymphocytes that can be used for cancer
immunotherapy. Since the balance of signals from activating and inhibitory receptors …

Natural killer cells are a promising platform for cancer immunotherapy. Natural killer cells
have high intrinsic killing capability, and the insertion of a chimeric antigen receptor can …